Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Ferrari Q3 Earnings, Revenue Rise; Raises 2026 Guidance

Ferrari Q3 Earnings, Revenue Rise; Raises 2026 Guidance

MT newswireMT newswire2026/11/03 10:55
06:55 AM EST, 11/03/2026 (MT Newswires) -- Ferrari (RACE) reported Q3 earnings Tuesday of 2.44 euros ($2.73) per diluted share, up from 2.14 euros a year earlier. Analysts polled by FactSet expected 2.36 euros. Revenue for the quarter ended Sept. 30 was 1.90 billion euros, up from 1.77 billion euros a year earlier. Analysts expected 1.90 billion euros. The company said it now expects 2026 adjusted diluted EPS of at least 9.85 euros, up from a prior forecast of at least 9.68 euros. Analysts polled by FactSet expect 9.83 euros. Ferrari also expects net revenue for the year of about 7.65 billion euros, up from a prior forecast of about 7.60 billion euros. Analysts polled by FactSet expect 7.64 billion euros.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment

According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.

智通财经•2026/11/06 08:27

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56